These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29171139)

  • 1. Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes.
    Tamborlane WV; Laffel LM; Weill J; Gordat M; Neubacher D; Retlich S; Hettema W; Hoesl CE; Kaspers S; Marquard J
    Pediatr Diabetes; 2018 Jun; 19(4):640-648. PubMed ID: 29171139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
    Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
    Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
    Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
    Forst T; Uhlig-Laske B; Ring A; Ritzhaupt A; Graefe-Mody U; Dugi KA
    Diabetes Obes Metab; 2011 Jun; 13(6):542-50. PubMed ID: 21352464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
    Covington P; Christopher R; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):499-512. PubMed ID: 18405788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.
    Schernthaner G; Barnett AH; Patel S; Hehnke U; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1078-86. PubMed ID: 24865132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
    Muskiet MHA; Tonneijck L; Smits MM; Kramer MHH; Ouwens DM; Hartmann B; Holst JJ; Touw DJ; Danser AHJ; Joles JA; van Raalte DH
    Diabetes Care; 2020 Nov; 43(11):2889-2893. PubMed ID: 32900785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
    Ross SA; Rafeiro E; Meinicke T; Toorawa R; Weber-Born S; Woerle HJ
    Curr Med Res Opin; 2012 Sep; 28(9):1465-74. PubMed ID: 22816729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
    Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
    Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
    Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.
    Cooper ME; Perkovic V; Groop PH; Hocher B; Hehnke U; Meinicke T; Koitka-Weber A; van der Walt S; von Eynatten M
    J Hypertens; 2019 Jun; 37(6):1294-1300. PubMed ID: 30540657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2013 Sep; 15(9):810-8. PubMed ID: 23464664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE).
    de Boer SA; Heerspink HJL; Juárez Orozco LE; van Roon AM; Kamphuisen PW; Smit AJ; Slart RHJA; Lefrandt JD; Mulder DJ
    Diabetes Obes Metab; 2017 Aug; 19(8):1147-1154. PubMed ID: 28244635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
    Kim ES; Deeks ED
    Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
    Fadini GP; Bonora BM; Albiero M; Zaninotto M; Plebani M; Avogaro A
    Cardiovasc Diabetol; 2017 Feb; 16(1):22. PubMed ID: 28183314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes.
    Sarashina A; Friedrich C; Crowe S; Patel S; Graefe-Mody U; Hayashi N; Horie Y
    J Diabetes Investig; 2016 Sep; 7(5):744-50. PubMed ID: 27180969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
    Tripolt NJ; Aberer F; Riedl R; Url J; Dimsity G; Meinitzer A; Stojakovic T; Aziz F; Hödl R; Brachtl G; Strunk D; Brodmann M; Hafner F; Sourij H
    Cardiovasc Diabetol; 2018 May; 17(1):71. PubMed ID: 29773079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.